| Population 2018 |
47 million |
| |
| | | | | | |
| Estimates of TB burdenº, 2018 |
Number (thousands) |
Rate
(per 100 000 population) |
| Total TB incidence |
4.4 |
(3.8–5.1) |
9.4 |
(8.1–11) |
| HIV-positive TB incidence |
0.31 |
(0.11–0.63) |
0.67 |
(0.23–1.4) |
| MDR/RR-TB incidenceºº |
0.24 |
(0.17–0.33) |
0.52 |
(0.36–0.71) |
| HIV-negative TB mortality |
0.26 |
(0.26–0.27) |
0.56 |
(0.55–0.57) |
| HIV-positive TB mortality |
0.048 |
(0.014–0.1) |
0.1 |
(0.03–0.22) |
| |
| | | | | | |
| Estimated proportion of TB cases with MDR/RR-TB, 2018 |
| New cases |
4.2% (2.9–5.8) |
| Previously treated cases |
18% (9.4–30) |
| |
| | | | | | |
| TB case notifications, 2018 |
|
| Total new and relapse |
4 500 |
| - % tested with rapid diagnostics at time of diagnosis |
26% |
| - % with known HIV status |
|
| - % pulmonary |
72% |
| - % bacteriologically confirmedººº |
85% |
| - % children aged 0-14 years |
7% |
| - % women |
34% |
| - % men |
59% |
| Total cases notified |
4 648 |
| |
| | | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2018 |
100% (89–120) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2018 |
7% (6–9) |
| |
| | | | | | |
| TB/HIV care in new and relapse TB patients, 2018 |
Number |
(%) |
| Patients with known HIV status who are HIV-positive |
|
|
| - on antiretroviral therapy |
|
|
| |
| | | | | | |
| Drug-resistant TB care, 2018 |
| % of bacteriologically confirmed TB cases tested for rifampicin resistance ººº |
| - New cases |
|
| - Previously treated cases |
|
| Laboratory-confirmed cases* |
MDR/RR-TB: , XDR-TB: |
| Patients started on treatment* ** |
MDR/RR-TB: , XDR-TB: |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
| |
| | | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2017 |
61% |
4 527 |
| Previously treated cases, excluding relapse, registered in 2017 |
73% |
1 125 |
| HIV-positive TB cases registered in 2017 |
52% |
217 |
| MDR/RR-TB cases started on second-line treatment in 2016 |
44% |
16 |
| XDR-TB cases started on second-line treatment in 2016 |
|
0 |
| |
| | | | | | |
| TB preventive treatment, 2018 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | | |
| TB financing, 2019 |
|
| National TB budget (US$ millions) |
|
| |
| | | | | | |
| º Ranges represent uncertainty intervals | | | | | |
| ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| ººº Calculated for pulmonary cases only | | | | | | |
| * Includes cases with unknown previous TB treatment history | | | | |
| ** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed | | |
| | | | | | |